Nov 16, 2022 / 01:30PM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
Thanks for joining us on our next session. I'm Michael Yee, Senior Biotechnology Analyst at Jefferies. Very happy to have up here on the stage the President of Moderna, Stephen Hoge. It's great to have you. Thanks for being here with us.
Questions and Answers:
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity AnalystObviously, a ton of stuff going on. You just reported earnings. We're in the middle of some sort of transition from pandemic to endemic. I think we were commenting here, I guess, we are in endemic because everyone is doing just fine, and we'll deal with that. But also, of course, a lot of important things near term on the platform.
And so I'd love to spend some time talking about, obviously, where we are with COVID and some of the big platform readouts that are going to happen, because I think this is as important as perhaps the Moderna story will obviously have exposure to COVID, but transition to talking about other things.
So maybe
Trustpilot
